The Newsroom

Investigations  /  05.22.2017

Kadmon Holdings, Inc.

Robbins Arroyo LLP Is Investigating the Officers and Directors of Kadmon Holdings, Inc. (KDMN) on Behalf of Shareholders

Robbins Arroyo LLP is investigating whether certain officers and directors of Kadmon Holdings, Inc. (NYSE: KDMN) violated federal securities laws in connection with the company’s “co-promotion” relationship with Valeant Pharmaceuticals, whose former employees were charged with fraud in November 2016. Kadmon, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics within autoimmune and fibrotic, oncology, and genetic diseases.

Kadmon Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Leonid Kandinov at (800) 350-6003, or you can complete the form below and we will contact you directly.

Shareholder Information







Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.
I have read the disclaimer information.



Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1-800-350-6003 or info@robbinsarroyo.com

Tell us your concerns